Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.71 |
| ▸ | LTA4H | P09960 | 1/20 | 0.64 |
| ▸ | POLB | P06746 | 3/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8351425 | 0.94 | SMN1; SMN2 (0.71) | SMN1; SMN2LTA4HPOLBKDM4EL3MBTL1 | |
| SCHEMBL12409045 | 0.93 | SMN1; SMN2 (0.74) | SMN1; SMN2LTA4HPOLBKDM4EL3MBTL1 | |
| SCHEMBL13963827 | 0.87 | SYK (0.71) | SMN1; SMN2POLBKDM4EL3MBTL1ALDH1A1 | |
| SCHEMBL11817599 | 0.87 | KDM4E (0.58) | SMN1; SMN2LTA4HPOLBKDM4EL3MBTL1 | |
| SCHEMBL19700704 | 0.87 | KDM4E (0.64) | SMN1; SMN2KDM4EL3MBTL1HTTALDH1A1 | |
| SCHEMBL12726118 | 0.85 | SMN1; SMN2 (0.71) | SMN1; SMN2LTA4HPOLBKDM4EL3MBTL1 | |
| SCHEMBL14453571 | 0.84 | SMN1; SMN2 (0.97) | SMN1; SMN2KDM4EL3MBTL1HTTALDH1A1 | |
| SCHEMBL9912418 | 0.84 | SMN1; SMN2 (0.74) | SMN1; SMN2LTA4HKDM4EL3MBTL1HTT | |
| SCHEMBL2323789 | 0.84 | LTA4H (0.66) | SMN1; SMN2LTA4HPOLBKDM4EALDH1A1 | |
| SCHEMBL264641 | 0.84 | LTA4H (0.62) | SMN1; SMN2LTA4HPOLBKDM4ETDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2443123-B1 | SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) | RIGEL PHARMACEUTICALS INC (US) | 2017-04-05 | — | — | EP | disclosed |
| EP-1951684-B1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | TARGEGEN INC (US) | 2016-07-13 | — | — | EP | disclosed |
| US-20120082702-A1 | NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MEYERS SQUIBB COMPANY | 2012-04-05 | — | — | US | disclosed |
| US-8138199-B2 | Use of bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-20090275582-A1 | Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases | IMPACT BIOMEDICINES, INC. | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275582-A1 | Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases | JAK2, TYK2, JAK3 | SMN1; SMN2 4746/4885LTA4H 3846/4885POLB 1540/4885 |
| US-20120082702-A1 | NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS | NADK, BTK, NAMPT | SMN1; SMN2 2328/4885LTA4H 1365/4885POLB 2024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.